红细胞药物递送系统的研究进展  

Research progress on erythrocyte drug delivery system

作　　者：杨根生[1] 金陈浩 徐书敏 杨庆良 郭钫元[1] 欧志敏[1] YANG Gensheng;JIN Chenhao;XU Shumin;YANG Qingliang;GUO Fangyuan;OU Zhimin(College of Pharmaceutical Science,Zhejiang University of Technology,Hangzhou 310014,China)

机构地区：[1]浙江工业大学药学院,浙江杭州310014

出　　处：《浙江工业大学学报》2020年第6期684-689,共6页Journal of Zhejiang University of Technology

基　　金：国家自然科学基金资助项目(21808206,51803181);浙江省自然科学基金资助项目(LY19B060012)。

摘　　要：载药纳米粒、脂质体、微球和微囊等微粒给药系统,成为近年来的研究热点,但其自身稳定性能较差,且给药后易被人体免疫系统捕获和清除,生物利用度低。红细胞作为内源性细胞,具有高生物安全性和低免疫原性等优点,是一种极具应用前景的新型药物递送系统,已成为相关领域的研究热点。基于此,综述了红细胞仿生给药系统的概况及研究进展,总结了基于红细胞的载药技术和方法,阐述了目前红细胞药物递送系统的优缺点及其发展趋势。Drug delivery systems with nanoparticles,liposomes,microspheres,microcapsules and other microparticles have become a research hotspot in recent years,which aims to enrich and improve studies of pharmacokinetics.However,these systems have poor stability and are easy to be captured and removed by the human immune system after drug delivery,leading to low bioavailability.Erythrocyte is endogenous cell with advantages of high biological safety and low immunogenicity,making it a new promising drug delivery system.This paper has reviewed general situation and research progress of the erythrocyte drug delivery system.The techniques and methods used for drug delivery in this system and their advantages and disadvantages have been summarized.In addition,future development of the erythrocyte drug delivery system has been discussed.

关 键 词：恶性肿瘤 红细胞药物递送系统 新型给药系统 细胞膜 

分 类 号：R945[医药卫生—微生物与生化药学]